Details for New Drug Application (NDA): 201751
✉ Email this page to a colleague
NDA 201751 describes ULTACAN, which is a drug marketed by Hansamed Inc and is included in two NDAs. Additional details are available on the ULTACAN profile page.
The generic ingredient in ULTACAN is articaine hydrochloride; epinephrine bitartrate. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the articaine hydrochloride; epinephrine bitartrate profile page.
The generic ingredient in ULTACAN is articaine hydrochloride; epinephrine bitartrate. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the articaine hydrochloride; epinephrine bitartrate profile page.
Summary for 201751
| Tradename: | ULTACAN |
| Applicant: | Hansamed Inc |
| Ingredient: | articaine hydrochloride; epinephrine bitartrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML) | ||||
| Approval Date: | Jul 11, 2017 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
